RET Inhibitor Demonstrates Efficacy in RET-Altered Thyroid Cancer
Treatment of RET-altered thyroid cancer with selpercatinib, a RET inhibitor, resulted in durable efficacy with a tolerable safety profile in a phase 1/2 trial.
Endocrine Cancer Mobile
ENDOCRINE CANCER ADVISOR
Endocrine Cancer News
The Twitter Effect on How Oncologists Conduct and Share Research
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Researchers Reveal Racial Disparities in Access to Remdesivir for Patients With Cancer and COVID-19
Black patients were half as likely to receive remdesivir as White patients, according to researchers from the CCC19.
Conflicts of Interest Continue to Plague Oncology Guidelines and Research
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Why Cancer Centers May Need to Rethink the Hard Sell to Patients
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
FDA: Unacceptable NDMA Levels Identified in Certain Metformin ER Products
Specifically, unacceptable levels of this potentially carcinogenic impurity have been identified in products manufactured by 5 different firms.
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Retevmo Gets Accelerated Approval for RET-Driven Lung, Thyroid Cancers
The FDA has granted accelerated approval to Retevmo™ (selpercatinib; Lilly).
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
Regular Medical Surveillance in World Trade Center Emergency Personnel May Explain Increased Rates of Thyroid Cancer
Higher incidence of thyroid cancer in World Trade Center-exposed emergency workers is likely due to greater detection of asymptomatic thyroid cancer.
Not Developing Any New Drugs Could Be EQRx’s Biggest Innovation
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
Aggressive Subtypes of Papillary Thyroid Cancer Deserve Increased Attention
Although papillary thyroid carcinoma subtypes are often lumped together, mortality risk varied greatly across subtypes.
“Medical Distancing” May Help Protect Cancer Patients From Exposure to COVID-19
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
First Human Clinical Trial in US to Test the Use of CRISPR-Modified T Cells in Cancer Answers Vital Questions
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.
Evidence Suggests B Cells Play a Role in Immunotherapy Response
New research shows that B cells — and not just T cells — influence whether patients respond to immunotherapy in melanoma, sarcoma, and kidney cancers.
The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
Therapeutic Advancements Have Facilitated Surgery Optimization, ASCO Officials Report
ASCO outlined advances in oncology that were the most clinically meaningful or had the biggest scientific impact from October 2018 through September 2019.
The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
No Link Found Between Hepatitis C Infection and Extrahepatic Cancers
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators.
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system.
Popular Genetic Tests Miss Many Cancer-Associated Genetic Variants, Particularly in Ethnic Minorities
The chance of missing a disease-causing variant can be as high as 100% across some groups.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
